Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02270957 · ClinicalTrials.gov registry record · Phase 2
Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches
A Phase 2 study, sponsored by Oklahoma Medical Research Foundation.
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT02270957 is a Phase 2 study that has completed, run by Oklahoma Medical Research Foundation. The registered enrollment target is 66 participants.
The verdict
NCT02270957, a Phase 2 study, has completed, sponsored by Oklahoma Medical Research Foundation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
This is a randomized, double blind, placebo controlled trial of abatacept for the treatment of lupus arthritis and other manifestations of lupus. Patients with lupus and at least 3 tender and 3 swollen joints and \</= 20 mg prednisone have other background immune suppressants withdrawn at entry. They can elect to receive up to a total of 320 mg depomedrol (in two or more injections) between the screening visit and the visit 2 months after dosing begins. Abatacept (125 mg) or placebo is administered in weekly subcutaneous doses. After 3 months of treatment patients who are not responding may elect to receive open label abatacept with or without additional standard of care therapies. Such patients are considered non responders. The primary endpoint is the British Isles Lupus Assessment Group Index (BILAG)-linked Combined Lupus Assessment (BICLA) which will require a clinically significant improvement in arthritis and other active features of lupus
Interventions
- OTHER Placebo
- BIOLOGICAL Abatacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2014-01 |
| Est. Completion | 2021-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02270957
The ClinicalTrials.gov registry entry for NCT02270957 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oklahoma Medical Research Foundation, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02270957 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02270957 about?
NCT02270957 is a clinical study titled "Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches". This is a randomized, double blind, placebo controlled trial of abatacept for the treatment of lupus arthritis and other manifestations of lupus. Patients with lupus and at least 3 tender and 3 swollen joints and \</= 20 mg prednisone have other background immune suppressants withdrawn at entry. The...
What is the current status of trial NCT02270957?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2014-01. Estimated completion is 2021-12.
What interventions are being tested in trial NCT02270957?
The interventions under investigation include: Placebo (OTHER), Abatacept (BIOLOGICAL).
Who is sponsoring clinical trial NCT02270957?
This trial is sponsored by Oklahoma Medical Research Foundation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.